The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Sourcing · Regulatory · continued

Pharmaceutical compounding rules, summarised from primary sources posts 151–164

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

VS
vial_slopeTL3Regular6 Mar 2025#151
citation_peak, post #115: Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported. Take the reasoning and check the arithmetic; I do not always get it right. Go to post

Pharmaceutical compounding rules is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.

0 likes in reply to #115 17mo
NH
n.hartmannTL26 Mar 2025#152

An honest declaration on pharmaceutical compounding rules: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.

2 likes 17mo
N
NLoughranTL3Regular6 Mar 2025#153

I read post #151 twice before replying, because I had assumed the opposite.

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

Adding it in case it saves somebody the afternoon it cost me.

14 likes 17mo
VM
v.malinowskiTL26 Mar 2025#154

Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.

For what it is worth, the same held on the two occasions I checked.

5 likes 17mo
CP
citation_peakTL3Regular6 Mar 2025#155
maintenance_mode, post #134: Confirming post #133 from a second method, which matters more than confirming it from a second person. Contradicting a claim in this subcategory is most useful when it comes with a link to the primary source and a date of access. Go to post

Small methodological point on pharmaceutical compounding rules: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.

13 likes in reply to #134 17mo
FY
f.yildizTL26 Mar 2025#156
LP
l.parkinsonTL2Member6 Mar 2025#157

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

If the premise is wrong, everything after it is decoration.

0 likes 17mo
MN
ma.nascimentoTL26 Mar 2025#158
DKwiatkowski, post #31: Where the pharmaceutical compounding rules reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for. Go to post

A compound in a compounding pathway in one country and unavailable in another is a common situation and produces most of the confusion here.

28 likes in reply to #31 17mo
SK
s.kimaniTL26 Mar 2025#159

On post #155 — agreed on the reasoning, with one qualification.

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

I would be glad to be shown a cleaner way of putting this.

19 likes 17mo
EP
e.piresTL26 Mar 2025#160
m.perrin, post #53: Agreed on all of that, and I have nothing to add to it. Go to post

Picking up post #159: that is the part I would want checked first.

I changed my mind about pharmaceutical compounding rules after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.

8 likes in reply to #53 17mo
MG
m.guerreroTL26 Mar 2025#161
ST
stopper_traceTL2Member6 Mar 2025#162

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

I have left out the parts I could not verify.

22 likes 17mo
NK
n.kaufmannTL26 Mar 2025#163

Building on post #160 rather than restating it.

Pharmaceutical compounding rules came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.

0 likes 17mo
VS
vial_slopeTL3Regular6 Mar 2025#164
h.jansen, post #72: Where I part company with post #69, and it is a narrow parting. An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence. Go to post

Post #162 put the caveat in the right place and I want to underline it.

Contradicting a claim in this subcategory is most useful when it comes with a link to the primary source and a date of access.

1 like in reply to #72 17mo
This topic was closed 90 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.
Moved from Vendor reports by t.vasquez. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

TopicParticipantsRepliesViewsActivity
Research-use-only labelling: what it means and what it does not — the long version
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. A labelling question, and I would like…
GLSHKKK+150 158 55k 14mo
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…
CRDPICCDJB+50 56 780 8mo
Coming back to: Research-use-only labelling: what it means and what it does not
Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. A labelling question, and I would like the answer to be about what the…
RDCCAAPSDO+45 50 39k 20mo
Follow-up: How compounding permissions changed when supply normalised
How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about compounding permissions in a thread last…
STNHSLSTJM+72 77 1.5k 1d
Import rules for personal quantities, by jurisdiction, dated
On the subject in the title: Import rules for personal quantities, by jurisdiction, dated Working notes rather than a conclusion. I was wrong about import rules for personal quantities in a thread last spring…
MDFNBRAN 3 60k 12mo

Related topics — sharing the tags MHRA, EMA, research use only

TopicParticipantsRepliesViewsActivity
About the Regulatory category
Research-use-only status, compounding rules, import restrictions, and the primary documents behind them. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
OBSLKEFNV 4 49k 4mo
Labelling requirements for research chemicals
Labelling requirements for research chemicals — setting out what I have, and where I think it stops being reliable. The question about labelling requirements for research chemicals that I actually want…
BNCGCCMLNN+5 9 45k 4mo
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…
MKJSMSRFF+81 87 35k 10mo
UK access routes, dated and sourced
UK access routes, dated and sourced Writing it up because I had to work it out twice and would rather nobody else did. Regional question, dated June 2026, because everything in this category expires. The…
NROJC 2 5.8k 15mo
Prescription portability between countries — the long version
On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. A narrow question about Prescription portability between countries,…
HVMRSC 2 182 21h